Clinical Trial Update: Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating CCT301 CAR-T therapy in adults with recurrent or refractory stage IV renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CCT301 CAR-T

Snippet

Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED